⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Zepbound (Tirzepatide) | Accelerate Your Fibrosis Research

Home/Drugs/Zepbound

Zepbound

Tirzepatide

Phase 3

Sponsor: Eli Lilly

Indication: MASH / Obesity

Mechanism of Action

GLP-1/GIP Dual Agonist

Target: GLP-1Target: GIP

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

RECRUITINGNCT07251803

GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound

Org:Medical University of South Carolina

RECRUITING

Relevant Publications (PubMed)

No recent publications found for Tirzepatide.

Validated Models

This drug has been validated in the following preclinical models:

NCT06976853

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Phase:PHASE2Org:Washington University School of Medicine

ACTIVE_NOT_RECRUITINGNCT06779929

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Org:Brigham and Women's Hospital

NOT_YET_RECRUITINGNCT06737042

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Phase:PHASE2Org:Gan and Lee Pharmaceuticals, USA

NOT_YET_RECRUITINGNCT07179120

Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

Phase:PHASE2Org:First Affiliated Hospital of Wenzhou Medical University

View all trials on ClinicalTrials.gov